Trial
NCT03464097
A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease
Phase IIITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Celgene
Collaborators
—
Condition
Crohn Disease
Intervention
Ozanimod
Why stopped
The study has terminated due to non-safety reasons; Business Objectives have changed.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-10-09